Compare Abeona Therapeutics Inc (ABEO) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Bill.com Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while Bill.com Holdings Inc trades at $48.22 (market cap $4.93B). The key difference: Bill.com Holdings Inc is far larger — about 11.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BILL | |
|---|---|---|
Market Cap | $421.19M | $4.93B |
Sector | Health | Technology |
52-Week High | $7.45 | $56.32 |
52-Week Low | $4.17 | $31.96 |
Enterprise Value | $276.10M | $4.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
BILL Holdings trades at $49.26, up 2.65% today, showing strong momentum with three consecutive earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth has accelerated from $642M in 2022 to $1.46B in 2025, with the company achieving positive net income for the first time. Recent leadership changes and operational efficiency initiatives, including a 30% workforce reduction, position the company for improved profitability.
The outlook remains positive with 56% analyst buy ratings and a consensus price target of $45.67, though current price exceeds this target. Key risks include high valuation multiples (P/E 213.91) and intense fintech competition. Upside catalysts include continued SMB adoption and AI-driven automation growth, while execution risks and market volatility present challenges for investors seeking exposure to the financial operations software sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
